Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study

Next Previous
X
Search
Trial Profile

Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 64Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary) ; Gallium (68Ga) gozetotide
  • Indications Prostate cancer
  • Focus Diagnostic use; First in man
  • Acronyms PROPELLER
  • Sponsors Clarity Pharmaceuticals

    • Most Recent Events

    • 17 Jul 2023 Results published in a Clarity Pharmaceuticals media release.
    • 17 Jul 2023 According to a Clarity Pharmaceuticals media release, results of this study has been awarded First Place in the Oncology, Clinical Therapy and Diagnosis category at the worlds most prestigious nuclear medicine conference, Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting.
    • 06 Jun 2023 Results assessing the safety and efficacy of 64Cu-SAR-bisPSMA in patients with prostate cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top